Intervention: Pibrentasvir
Trial phase: Phase 3
ATC code: J05AP57
SMILES: COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc2cc([C@H]3CC[C@H](c4cc5nc([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)[C@@H](C)OC)[nH]c5cc4F)N3c3cc(F)c(N4CCC(c5ccc(F)cc5)CC4)c(F)c3)c(F)cc2[nH]1)[C@@H](C)OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 253
Group description: Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.

Participants receive glecaprevir (300mg)/pibrentasvir (120mg): glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
Eligibility criteria:
Inclusion Criteria:

Have voluntarily signed the informed consent form.
18 years of age or older.
Chronic HCV infection as defined by anti-HCV antibody or HCV RNA detection for greater than 6 months.
HCV RNA plasma ≥ 10,000 IU/ml at screening.
HCV genotype 1-6.
HCV treatment naïve (no prior treatment with an approved or investigation anti-HCV medication).
Stage F0-3, based on: hepatic elastography <12.5 kPa on Fibroscan® or APRI <1.0.

If co-infection with HIV is documented, the subject must meet the following criteria:

ART naïve with CD4 T cell count >500 cells/mm3; OR
On a stable ART regimen (containing only permissible ART - see protocol section 3.2) for >8 weeks prior to screening visit, with CD4 T cell count >200 cells/mm3 and a plasma HIV RNA level below the limit of detection.
Negative pregnancy test at screening and baseline (females of childbearing potential only).
All fertile females must be using effective contraception during treatment and during the 30 days after treatment end.

Exclusion Criteria:

History of any of the following:

Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with the participant treatment, assessment or compliance with the protocol; participants currently under evaluation for a potentially clinically significant illness (other than HCV) are also excluded.
Clinical hepatic decompensation (i.e. ascites, encephalopathy or variceal haemorrhage).
Solid organ transplant.
History of severe, life-threatening or other significant sensitivity to any excipients of the study drugs.

Any of the following lab parameters at screening:

ALT > 10 x ULN
AST > 10 x ULN
Direct bilirubin > ULN
Platelets < 90,000/μL (cells/mm3) if Fibroscan® <12.5 kPa OR < 150,000/μL (cells/mm3) if Fibroscan® is unavailable and patient is included with APRI <1
Creatinine clearance (CLcr) < 50 mL/min
Haemoglobin < 12g/dL for males; <11g/dL for females
Albumin < LLN
INR > 1.5 ULN unless subject has known haemophilia or is stable on an anticoagulant regimen affecting INR
Pregnant or breastfeeding female.
HBV infection (HBsAg positive).
Use of prohibited concomitant medications as described in protocol section 5.2.
Chronic use of systemically administered immunosuppressive agents (e.g. prednisone equivalent > 10 mg/day for >2 weeks).
Therapy with any anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) ≤6 months prior to the first dose of study drug.
Any investigational drug ≤6 weeks prior to the first dose of study drug.
Ongoing severe psychiatric disease as judged by the treating physician.
Positive result of a urine drug screen at the Screening Visit for opiates, barbiturates, amphetamines, cocaine, benzodiazepines, phencyclidine, propoxyphene, or alcohol, with the exception of a positive result (including methadone) associated with documented short-term use or chronic stable use of a prescribed medication in that class.
Injecting drug use within the previous six months.
Inability or unwillingness to provide informed consent or abide by the requirements of the study.